Roche’s entrectinib for gene fusion-positive cancers has shown promising results in a range of paediatric cancers in an early-stage trial, earning it a spotlight position at a pre-ASCO pres
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
